ALDX
Aldeyra Therapeutics, Inc.
Next earnings Aug 5, 2026 · consensus $-0.11 EPS
$1.83
▲ +1.67%$1.83▼ -40.68%
over 1Y
L $1.24EODHDH $5.89
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.7%
1W-10.7%
1M+7.0%
3M+3.4%
YTD-60.8%
1Y-40.7%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Conservative balance sheet (liabilities/equity 0.63x).
Return on equity -76.5% · latest
Aldeyra Therapeutics, Inc. shows limited reported revenue, and -76.5% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$56.2M | -$62.7M | -$42.8M | -$60.1M | -$35.3M |
| Net income | -$57.8M | -$62.0M | -$37.5M | -$55.9M | -$33.8M |
| Diluted EPS | -$1.07 | -$1.06 | -$0.64 | -$0.94 | -$0.56 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$55.3M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-30.7%
FCF yield-30.3%
Quality & risk
ROIC (est.)-46.8%
Free cash flow-$33.3M
Total debt$15.2M
Net cash$54.8M
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗3Period ending 2026-06-092026-06-11open ↗8-KPeriod ending 2026-06-092026-06-10open ↗4Period ending 2026-06-032026-06-05open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-07open ↗
Frequently asked
- Is Aldeyra Therapeutics, Inc. (ALDX) a buy?
- ALDX currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.63x).
- What is Aldeyra Therapeutics, Inc.'s quality score?
- ALDX scores 58.333333333333336/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001341235, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 6:05:12 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.